According to the Smart Finance APP, New Journey (002219.SZ) announced to further strengthen the company's influence in existing business areas, enhance the development and layout capabilities in the Medical Services field, optimize the company's capital structure, and enhance the comprehensive competitiveness of the company. The company's wholly-owned subsidiary SiChuan FuHui Pharmaceutical Co., Ltd. (hereinafter referred to as "FuHui Pharmaceutical"), SiChuan YongDao Medical Investment Management Co., Ltd. (hereinafter referred to as "YongDao Medical") and ShanDong Railroads Development Fund Co., Ltd. (hereinafter referred to as "Railroads Fund") and ShanDong LiSheng Investment Co., Ltd. (hereinafter referred to as "ShanDong LiSheng") jointly invested to establish the Qingdao New Journey Medical Industry Investment Center (Limited Partnership), and signed the "Qingdao New Journey Medical Industry Investment Center (Limited Partnership) Partnership Agreement" and the "Supplementary Agreement to the Qingdao New Journey Medical Industry Investment Center (Limited Partnership) Partnership Agreement"; it was agreed that the company would provide buyback and shortfall supplement obligations for the investment principal and returns of the partner enterprise priority limited partner Railroads Fund, and signed the "Qingdao New Journey Medical Industry Investment Center (Limited Partnership) Buyback and Shortfall Supplement Agreement". The capital scale of the partnership is 0.322 billion yuan.

After the company acquires 100% equity of Chongqing New Journey Medical Management Co., Ltd. (referred to as "Chongqing New Journey"), the partnership plans to acquire 100% equity of Chongqing New Journey. The partnership will only invest in holding shares of Chongqing New Journey during its existence and will not invest in Other projects.

While ensuring the steady development of the company's main business, this investment allocates an appropriate scale of social capital to jointly participate in the acquisition of Chongqing New Journey, which helps expand the company's main business and optimize the investment income structure, strengthening the company's comprehensive competitiveness. This investment aligns with the company’s strategic development plan, guided by the Health China strategy, supporting Chinese-style modernization and actively serving the aging population strategy, adhering to the mission of "allowing everyone to enjoy better health services" and aiming to build a management-style medical system with Chinese characteristics, while working to enhance the company’s operational capabilities and achieve performance growth.